BTIG Research Reiterates Hold Rating for Transenterix (TRXC)

BTIG Research restated their hold rating on shares of Transenterix (NYSEAMERICAN:TRXC) in a report published on Monday, December 18th.

A number of other brokerages also recently weighed in on TRXC. Stifel Nicolaus raised their target price on Transenterix from $3.75 to $4.00 and gave the company a buy rating in a report on Tuesday, October 31st. Ladenburg Thalmann Financial Services set a $5.00 target price on Transenterix and gave the company a buy rating in a report on Friday, October 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $2.61.

Shares of Transenterix (NYSEAMERICAN:TRXC) remained flat at $$1.99 during trading hours on Monday. The company had a trading volume of 1,959,453 shares, compared to its average volume of 2,189,200. The firm has a market cap of $408.45, a price-to-earnings ratio of -3.21 and a beta of 2.02. Transenterix has a 52 week low of $0.45 and a 52 week high of $5.00.

In related news, CFO Joseph P. Slattery sold 529,609 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $2.80, for a total transaction of $1,482,905.20. Following the sale, the chief financial officer now owns 440,974 shares of the company’s stock, valued at approximately $1,234,727.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Todd Pope sold 600,000 shares of the firm’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $3.68, for a total value of $2,208,000.00. Following the sale, the insider now directly owns 462,644 shares in the company, valued at approximately $1,702,529.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,462,609 shares of company stock worth $4,666,595.

A hedge fund recently raised its stake in Transenterix stock. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Transenterix Inc (NYSEAMERICAN:TRXC) by 87.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 79,150 shares of the medical instruments supplier’s stock after purchasing an additional 37,000 shares during the period. Ladenburg Thalmann Financial Services Inc. owned 0.05% of Transenterix worth $113,000 at the end of the most recent quarter.

ILLEGAL ACTIVITY WARNING: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix and related companies with's FREE daily email newsletter.

Leave a Reply